FDA Warns Allergan Over Breast Implant Studies
The U.S. Food and Drug Administration on Thursday sent a warning letter to Allergan for failing to comply with requirements to conduct studies assessing the long-term safety and risks of recalled...To view the full article, register now.
Already a subscriber? Click here to view full article